On September 29, 2026, Dyne Therapeutics announced additional one-year clinical data from the multiple ascending dose portion of its Phase 1/2 ACHIEVE trial evaluating zeleciment basivarsen for myotonic dystrophy type 1. The pooled dose group (N=25-26) demonstrated sustained functional improvement across multiple measures, including a 3.2-second decrease in video hand-opening time at six months and significant gains in muscle strength and patient-reported outcomes at twelve months compared to baseline and natural history cohorts. Safety data through April 2026 showed a favorable profile with no related serious adverse events. The company expects topline data from the registrational expansion cohort in Q1 2027, supporting a potential U.S. Accelerated Approval BLA submission in Q3 2027. Dyne Therapeutics operates in the biotechnology industry and develops therapeutics for genetically driven neuromuscular diseases.
